Basilea Pharmaceutica AG Asset Resilience Ratio
Basilea Pharmaceutica AG asset resilience ratio. Basilea Pharmaceutica AG (BSLN) has an Asset Resilience Ratio of 51.58% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BSLN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Basilea Pharmaceutica AG (2002–2025)
Asset resilience ratio of Basilea Pharmaceutica AG from 2002 to 2025. This chart shows how Basilea Pharmaceutica AG's Asset Resilience Ratio has changed over time. See BSLN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Basilea Pharmaceutica AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BSLN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF128.37 Million | 51.58% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF128.37 Million | 51.58% |
Asset Resilience Insights
- Very High Liquidity: Basilea Pharmaceutica AG maintains exceptional liquid asset reserves at 51.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Basilea Pharmaceutica AG Industry Peers by Asset Resilience Ratio
Compare Basilea Pharmaceutica AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Basilea Pharmaceutica AG Asset Resilience Ratio by Year (2002–2025)
Basilea Pharmaceutica AG asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Basilea Pharmaceutica AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 94.11% | CHF265.39 Million ≈ $335.53 Million |
CHF282.00 Million ≈ $356.52 Million |
+52.71pp |
| 2024-12-31 | 41.40% | CHF106.72 Million ≈ $134.93 Million |
CHF257.76 Million ≈ $325.88 Million |
-18.42pp |
| 2023-12-31 | 59.82% | CHF103.67 Million ≈ $131.06 Million |
CHF173.29 Million ≈ $219.08 Million |
+14.56pp |
| 2022-12-31 | 45.26% | CHF99.96 Million ≈ $126.38 Million |
CHF220.85 Million ≈ $279.21 Million |
+6.84pp |
| 2021-12-31 | 38.42% | CHF95.00 Million ≈ $120.11 Million |
CHF247.27 Million ≈ $312.61 Million |
-10.18pp |
| 2020-12-31 | 48.60% | CHF111.67 Million ≈ $141.18 Million |
CHF229.79 Million ≈ $290.52 Million |
-11.48pp |
| 2019-12-31 | 60.08% | CHF133.05 Million ≈ $168.21 Million |
CHF221.47 Million ≈ $279.99 Million |
-5.81pp |
| 2018-12-31 | 65.89% | CHF185.63 Million ≈ $234.69 Million |
CHF281.75 Million ≈ $356.21 Million |
+5.91pp |
| 2017-12-31 | 59.98% | CHF210.62 Million ≈ $266.29 Million |
CHF351.17 Million ≈ $443.97 Million |
-2.76pp |
| 2016-12-31 | 62.74% | CHF205.63 Million ≈ $259.97 Million |
CHF327.76 Million ≈ $414.37 Million |
+49.79pp |
| 2015-12-31 | 12.95% | CHF51.62 Million ≈ $65.27 Million |
CHF398.74 Million ≈ $504.11 Million |
-14.25pp |
| 2014-12-31 | 27.20% | CHF70.00 Million ≈ $88.50 Million |
CHF257.38 Million ≈ $325.40 Million |
-24.51pp |
| 2013-12-31 | 51.71% | CHF155.00 Million ≈ $195.96 Million |
CHF299.76 Million ≈ $378.97 Million |
+19.74pp |
| 2012-12-31 | 31.97% | CHF120.00 Million ≈ $151.71 Million |
CHF375.34 Million ≈ $474.54 Million |
+21.43pp |
| 2011-12-31 | 10.54% | CHF25.00 Million ≈ $31.61 Million |
CHF237.09 Million ≈ $299.75 Million |
-36.84pp |
| 2010-12-31 | 47.39% | CHF150.00 Million ≈ $189.64 Million |
CHF316.54 Million ≈ $400.20 Million |
+15.93pp |
| 2009-12-31 | 31.46% | CHF65.00 Million ≈ $82.18 Million |
CHF206.61 Million ≈ $261.21 Million |
-34.06pp |
| 2008-12-31 | 65.52% | CHF215.00 Million ≈ $271.82 Million |
CHF328.13 Million ≈ $414.84 Million |
+10.26pp |
| 2007-12-31 | 55.26% | CHF255.00 Million ≈ $322.39 Million |
CHF461.45 Million ≈ $583.40 Million |
-13.67pp |
| 2006-12-31 | 68.94% | CHF140.00 Million ≈ $177.00 Million |
CHF203.09 Million ≈ $256.76 Million |
-9.32pp |
| 2005-12-31 | 78.26% | CHF200.00 Million ≈ $252.85 Million |
CHF255.56 Million ≈ $323.10 Million |
+19.22pp |
| 2004-12-31 | 59.04% | CHF136.25 Million ≈ $172.26 Million |
CHF230.78 Million ≈ $291.77 Million |
+57.87pp |
| 2003-12-31 | 1.17% | CHF1.25 Million ≈ $1.58 Million |
CHF107.02 Million ≈ $135.30 Million |
-46.00pp |
| 2002-12-31 | 47.17% | CHF71.00 Million ≈ $89.76 Million |
CHF150.51 Million ≈ $190.29 Million |
-- |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more